BIBO 3304 trifluoroacetate is a peptide derivative stabilized in TFA salt form to facilitate solubility and handling. The sequence supports studies of ligand-receptor interactions and conformational adaptability. Researchers apply it to evaluate structural determinants guiding peptide recognition. Its formulation enhances reproducible biophysical assays.
CAT No: PI-017
CAS No:191868-14-1
Synonyms/Alias:191868-14-1;BIBO 3304 TRIFLUOROACETATE;BIBO3304;BIBO3304 (TFA);BIBO3304 TFA;BIBO-3304;BIBO 3457;BIBO-3457;O35HK034KO;(2R)-N-[[4-[(carbamoylamino)methyl]phenyl]methyl]-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]pentanamide;2,2,2-trifluoroacetic acid;(R)-2-(2,2-Diphenylacetamido)-5-guanidino-N-(4-(ureidomethyl)benzyl)pentanamide 2,2,2-trifluoroacetate;217977-06-5;Benzeneacetamide, N-((1S)-1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-, mono(trifluoroacetate);(R)-N-(4-(aminocarbonylaminomethyl)-phenyl)methyl-N(2)-(diphenylacetyl)-argininamide trifluoroacetate;BIBO 3304;BIBO 3304 TRIFLUOROACETATE SALT;LS-28466;UNII-O35HK034KO;SCHEMBL649618;CHEMBL5303539;FBMCYYWIBYEOST-GJFSDDNBSA-N;GLXC-02410;EX-A9290;AKOS040732600;AC-36944;Benzeneacetamide, N-((1R)-1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-, trifluoroacetate (1:1);DA-51100;HY-107725;CS-0029393;E74996;Q27285259;BENZENEACETAMIDE, N-((1R)-1-((((4-(((AMINOCARBONYL)AMINO)METHYL)PHENYL)METHYL)AMINO)CARBONYL)-4-((AMINOIMINOMETHYL)AMINO)BUTYL)-.ALPHA.-PHENYL-, MONO(TRIFLUOROACETATE);BENZENEACETAMIDE, N-((1R)-1-((((4-(((AMINOCARBONYL)AMINO)METHYL)PHENYL)METHYL)AMINO)CARBONYL)-4-((AMINOIMINOMETHYL)AMINO)BUTYL)-.ALPHA.-PHENYL-, TRIFLUOROACETATE (1:1);Benzeneacetamide, N-((1R)-1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-, mono(trifluoroacetate);BENZENEACETAMIDE, N-(1-((((4-(((AMINOCARBONYL)AMINO)METHYL)PHENYL)METHYL)AMINO)CARBONYL)-4-((AMINOIMINOMETHYL)AMINO)BUTYL)-.ALPHA.-PHENYL-, (R)-, MONO(TRIFLUOROACETATE);Benzeneacetamide, N-(1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-, (R)-, mono(trifluoroacetate);
Chemical Name:(2R)-N-[[4-[(carbamoylamino)methyl]phenyl]methyl]-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]pentanamide;2,2,2-trifluoroacetic acid
BIBO 3304 trifluoroacetate is a synthetic, non-peptide antagonist that selectively targets neuropeptide Y (NPY) Y1 receptors. As a small molecule compound, it is widely recognized in neuropharmacology and receptor biology for its high specificity and affinity for the Y1 receptor subtype, making it an essential tool for dissecting the physiological and biochemical roles of NPY signaling. The trifluoroacetate salt form enhances its solubility and handling properties, supporting its use in a variety of in vitro and in vivo research contexts. BIBO 3304 trifluoroacetate has become a standard reference compound for studies aiming to elucidate the mechanisms underlying neuropeptide-mediated processes, particularly those involving appetite regulation, anxiety, and cardiovascular function.
Receptor characterization: In receptor pharmacology studies, BIBO 3304 trifluoroacetate is extensively employed to delineate the functional roles of NPY Y1 receptors. By selectively inhibiting Y1 receptor activity, researchers can distinguish between the contributions of different NPY receptor subtypes in cellular signaling pathways. This capability is crucial for mapping receptor distribution, understanding ligand-receptor interactions, and validating the specificity of novel ligands or antagonists in experimental models.
Signal transduction research: The compound is instrumental in dissecting downstream signaling cascades initiated by NPY binding to Y1 receptors. By blocking Y1-mediated responses, scientists can analyze the activation of second messenger systems, such as cyclic AMP or intracellular calcium flux, and uncover the molecular basis of NPY-driven effects in neuronal and peripheral tissues. Such studies contribute to a more detailed understanding of G protein-coupled receptor (GPCR) signaling networks and their modulation by endogenous and synthetic ligands.
Behavioral neuroscience: BIBO 3304 trifluoroacetate is frequently utilized in animal models to investigate the behavioral consequences of selective Y1 receptor antagonism. Its use allows researchers to explore the involvement of NPY signaling in feeding behavior, anxiety-like responses, stress adaptation, and other neurobehavioral phenomena. By isolating the specific impact of Y1 receptor blockade, these studies provide valuable insights into the neurochemical regulation of complex behaviors and the potential for targeting NPY pathways in neuropsychiatric research.
Cardiovascular physiology: The selective antagonistic properties of BIBO 3304 trifluoroacetate make it a valuable probe for examining the role of NPY Y1 receptors in cardiovascular regulation. Experimental protocols often employ the compound to assess its influence on vascular tone, blood pressure modulation, and cardiac contractility in isolated tissue preparations or whole-animal systems. These investigations help clarify the contribution of Y1 receptor signaling to autonomic control and vascular homeostasis.
Pharmacological profiling: The compound serves as a benchmark antagonist in drug discovery and screening programs focused on NPY receptor modulators. Its well-characterized selectivity and potency enable the validation of assay systems, facilitate structure-activity relationship (SAR) studies, and support the identification of novel therapeutic candidates targeting the NPY system. By providing a reliable reference point, BIBO 3304 trifluoroacetate enhances the rigor and reproducibility of pharmacological investigations aimed at modulating neuropeptide signaling pathways.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More